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Abstract
Background: Although depression is associated with changes in the hypothalamic-pituitary-thyroid axis, its
relationship with subclinical hypothyroidism (SCH) is controversial. To date, there is a lack of data on the
improvement of depressive symptoms with levothyroxine therapy among individuals with coexistent SCH.
Methods: We conducted a meta-analysis to evaluate the association between SCH and depression including 1) the
prevalence of depression in SCH (with a sub-analysis of the geriatric cohort), 2) thyroid stimulating hormone (TSH)
level among patients with depression and 3) the effect of levothyroxine therapy among patients with SCH and
coexistent depression.
Results: In a pooled analysis of 12,315 individuals, those with SCH had higher risk of depression than euthyroid
controls (relative risk 2.35, 95% confidence intervals [CI], 1.84 to 3.02; p < 0.001). Geriatric cohort with SCH had a 1.7-
fold higher risk of depression compared with healthy controls (odds ratio 1.72, CI, 1.10 to 2.70; p = 0.020). There was
no difference in the mean TSH level between individuals with depression and healthy controls (2.30 ± 1.18 vs. 2.13
± 0.72 mIU/L, p = 0.513). In individuals with SCH and coexistent depression, levothyroxine therapy was neither
associated with improvement in the Beck Depression Inventory scoring (pooled d + = − 1.05, CI -2.72 to 0.61; p = 0.
215) nor Hamilton Depression Rating Scale (pooled d + = − 2.38, CI -4.86 to 0.10; p = 0.060).
Conclusion: SCH has a negative impact on depression. Early and routine screening of depression is essential to
prevent morbidity and mortality. However, the use of levothyroxine among patients with SCH and coexistent
depression needs to be individualized.
Keywords: Subclinical hypothyroidism, Depression, Thyroid stimulating hormone, Levothyroxine
Background
Neuropsychiatric disorders account for approximately 14%
of the global burden of disease [1]. Depression, being one of
the common chronically disabling disorders, can lead to poor
quality of life [1, 2]. On the other hand, thyroid hormones
(free triiodothyronine [fT3] and free thyroxine [fT4])
which are widely distributed in the central nervous sys-
tem, regulate the neuronal growth and form synapses
between neurons [3]. Given that depression is known to
be associated with changes in the hypothalamic-pituitar-
y-thyroid (HPT) axis [4], studies have reported its positive
correlation with overt hypothyroidism [5]. However, its re-
lationship with subclinical hypothyroidism (SCH) is not
well established [6].
SCH is defined as an elevated thyroid stimulating hor-
mone (TSH) with normal fT4 and fT3 levels. It affects 3
to 8.5% of the general population with a female prepon-
derance, and a higher rate up to 20% among elderly
people [7, 8]. This diagnosis is often overlooked espe-
cially when laboratory tests are not readily available, as
these individuals with SCH tend to present with subtle
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and non-specific symptoms [9]. The debilitating effect of
SCH on cardiovascular morbidity and mortality has
gained increasing attention, suggesting that SCH is an
independent risk factor for atherosclerotic cardiovascu-
lar disease [10, 11]. However, its association with depres-
sion remains controversial at large, with some studies
indicated that SCH had the same propensity with overt
hypothyroidism, while the others reported conflicting
findings [7, 8, 12–24]. These inconsistent results could
be attributed to the heterogeneous study populations,
small sample size, lack of control arm for comparison
and differences in study design.
To date, individuals with SCH are recommended to be ini-
tiated with levothyroxine replacement therapy only when
their TSH level is above 10 mIU/L or if they are symptom-
atic, attempting pregnancy, have positive thyroid auto-
immunity or cardiovascular risk factors, especially
hypertension and hyperlipidemia [25, 26]. However, there is
a lack of solid evidence in support of the use of levothyroxine
therapy to improve mental health outcomes [27]. Hence, we
performed an updated meta-analysis to evaluate the correl-
ation between these two entities and the effect of levothyrox-
ine therapy.
Methods
We performed a systematic search of all English-language
medical literature published from inception till June 2017
using PubMed, CINAHL and OVID electronic databases.
We used MeSH headings of “subclinical hypothyroidism”,
“thyroid”, “depression”, “thyroxine”, “geriatric” and “eld-
erly”. We also reviewed references of the original article,
reviews and clinical guidelines to identify additional eli-
gible trials. Two independent reviewers (LHH and LLL)
screened the titles and abstracts obtained through the
electronic search and analysed the full-text articles. All du-
plicates were removed. Whenever needed, we contacted
the authors to obtain either the full-text article or for
clarification of the missing data. If the data were not pro-
vided numerically, it would be read off graphs. Two re-
viewers (LHH and LLL) extracted data from eligible
studies independently using standard template, including
authors, country of study conduct, study design, sample
size, age, mean TSH levels, prevalence of major depression
disorder (MDD) and the depression scores (based on the
different depression scoring systems).
The analyses were divided into three parts. For part I,
we examined the prevalence of depression in individuals
with SCH compared with healthy controls. We also eval-
uated the mean depression scores among individuals
with SCH, compared with their euthyroid counterparts
based on the depression scales used. We performed a
subgroup analysis on geriatric population, defined as
those aged 60 years and above according to the United
Nation’s classification [28]. For part II, we analysed the
mean TSH level in individuals with depression com-
pared with those without underlying psychiatric disor-
ders. For part III, we evaluated the effect of
levothyroxine replacement therapy on depressive symp-
toms among individuals with SCH.
Study selection
For part I, we included studies which reported individ-
uals who were diagnosed with SCH. Only case-control
studies that either compared the prevalence of depres-
sion or the mean depression scores in SCH cohort with
euthyroid/healthy controls were eligible. We excluded
studies that included individuals who had been treated
for thyroid disorders. Among the 15 studies included,
there were nine questionnaires used to evaluate depres-
sion. Beck Depression Inventory (BDI) scoring and
Hamilton Depression Rating Scale (HDRS) were the
most commonly administered questionnaires, which
were analysed in current meta-analysis.
For part II, we included only studies that assessed indi-
viduals with depression using standard depression as-
sessment tools, such as the HDRS, Structural Clinical
Interview for Diagnostic and Statistical Manual of Men-
tal Disorders, Third Edition, Revised (DSM-III-R) and
Fourth Edition (DSM-IV), and compared the mean TSH
with those not known to have psychiatric disorders.
For part III, either randomized controlled trials or
case-control studies that evaluated the effect of levothyr-
oxine therapy in individuals with SCH and coexistent
depression were included. Similar to part I, we analysed
studies which used BDI and/or HDRS scoring only.
Quality assessment
Two reviewers (LHH and LLL) independently appraised
the quality of reporting of all included studies using the
Newcastle-Ottawa Scoring (NOS) Scale for Case-Control
Studies (Appendix). Any discrepancies were resolved by a
third reviewer (LHS). The NOS scale was developed to as-
sess the quality of non-randomized case-control studies
for interpretation of meta-analysis results. It uses a “star
system” which judges the studies in three broad categor-
ies, namely the selection of study group, group compar-
ability and ascertainment of outcome of interest
(“Exposure”). Each study can be awarded a maximum of
one star for each numbered item (four in “Selection” cat-
egory and three in “Exposure” category), and a maximum
of two stars in the “Comparability” category. The max-
imum score is 10.
Statistical analysis
All data analyses were performed using Stats Direct (ver-
sion 2.7.9). Study characteristics were summarized. De-
scriptive statistics were shown as either mean ± standard
deviation (SD), median (interquartile range, IQR) or
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number (percentages). We calculated the prevalence of
depression in patients with SCH. The presence of
heterogeneity between the trials was tested using the
I2 statistic. An I2 value of more than 75% indicates
significant heterogeneity. Due to the moderate and
high heterogeneity (I2 ≥ 80% and ≥ 90%, respectively),
data were pooled using the DerSimonian-Laird
random-effects modelling. Pooled effect size (d+)
was presented along with 95% confidence interval
(CI) if the mean and SD of endpoint measures were
reported in original articles. If the Cochrane Q test
result was significant, we pooled the data using the
DerSimonian–Laird random-effects modelling; other-
wise, Hedges-Olkin fixed-effects modelling was used.
Results
Figure 1 shows the flow of studies selection. Initial
search identified 3647 articles and yielded 21 full-text
articles after abstracts screening and duplicates re-
moval. Out of these 21 articles, 15 were included in
part I analysis, six into part II and III analyses,
respectively.
Part I - prevalence of depression in SCH
Table 1 summarizes the study characteristics. A total of
12,315 individuals (1700 [13.8%] with SCH) from 15 arti-
cles were included in this analysis. The sample sizes
ranged from 22 to 8214. Six studies involved
community-dwelling healthy individuals [12, 17, 20, 21,
23, 29] while the remaining nine single-centre studies re-
cruited out-patients who were investigated for suspected
SCH [7, 13–16, 19, 22, 24, 30]. Eight studies reported
the mean depression scores between individuals with
SCH and healthy controls, of which five used HDRS [12,
13, 15, 16, 22] and three used BDI [17, 23, 24]. All other
studies used different but validated scales to diagnose
depression.
Overall, individuals with SCH were older compared
with healthy controls (51.9 ± 17.5 vs. 50.2 ± 17.4 years, p
= 0.020). The mean TSH in individuals with SCH was
significantly higher than healthy controls (16.20 ± 24.75
vs. 2.09 ± 0.57 mIU/L; p < 0.001). Six studies found a
higher prevalence of depression among individuals with
SCH compared with controls [7, 12, 14, 19, 23, 24], al-
though only three studies achieved statistically signifi-
cant difference [7, 14, 30]. Five studies showed higher
Fig. 1 PRISMA search strategy
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depression scores among patients with SCH than control
group [12, 16, 22–24]. Five other studies showed no
difference in the number of individuals with depres-
sion between SCH and control group [8, 15, 20, 21,
30], whereas three found no difference in the depres-
sion scores [13, 15, 17]. However, pooled analysis
showed that individuals with SCH had higher risk of
depression compared with euthyroid controls (relative
risk 2.36, 95% CI 1.84 to 3.02; p < 0.001) (Fig. 2).
Compared with healthy controls, there was no signifi-
cant difference in the depression scores among indi-
viduals with SCH, using either BDI scoring (10.85 ±
4.97 vs. 8.1 ± 2.82; p = 0.126) or HDRS scale (8.02 ±
2.44 vs. 5.66 ± 2.59; p = 0.312, 95% CI -2.22 to 6.70).
In geriatric cohort with SCH, four studies evalu-
ated the prevalence of depression [8, 14, 20, 30], of
which two recruited eligible individuals from single
centre out-patient clinics [14, 30] and another two
involved community-dwelling healthy controls [8,
20]. Their mean age did not differ from the euthyr-
oid controls (77.5 ± 3.3 vs. 77.5 ± 2.5 years; p = 0.770).
The mean TSH was higher among SCH individuals
than euthyroid controls (6.15 ± 0.91 vs. 2.19 ± 0.13
mIU/L; p < 0.001). Two studies found a higher preva-
lence of depression between elderly with SCH com-
pared to controls [14, 30]. When we pooled the data
from these four studies, elderly individuals with SCH
had a 1.7-fold higher risk of depression than healthy
controls (odds ratio 1.72, 95% CI 1.10 to 2.70; p =
0.020) (Fig. 3).
Part II - TSH level in depression
Table 2 shows the characteristics of seven
cross-sectional articles involving 7135 individuals, of
whom 4942 (80.3%) were men. Three studies recruited
individuals who were hospitalized for psychiatric dis-
order without prevalent diseases such as metabolic,
autoimmune and other endocrine diseases, infections
and inflammatory disorders [31–33]. Two studies in-
volved individuals seen in the psychiatric out-patient
clinics [34, 35], three from psychiatric wards [31–33]
whereas the other two studies selected individuals from
the elderly community [36, 37]. All studies reported
mean TSH of the study cohort. Five studies reported the
prevalence of SCH among those diagnosed with depres-
sion [31–33, 35, 36].
Among 753 (10.6%) individuals with depression, 429
(57.0%) were men. The mean age was higher among in-
dividuals with depression than healthy controls (56.6 ±
13.3 vs. 52.2 ± 15.9 years; p = 0.180). There was no differ-
ence in mean TSH between individuals with depression
and healthy controls (2.30 ± 1.18 vs. 2.13 ± 0.72 mIU/L;
p = 0.513).
Part III - effect of levothyroxine on depressive symptoms
Six papers which involved a total of 266 individuals
assessed the improvement of depression scores with
levothyroxine therapy in the SCH cohort. Three papers
utilized BDI scoring [17, 24, 38], whereas the remaining
three used HDRS [13, 16, 22].
Fig. 2 Risk of depression among patients with subclinical hypothyroidism
Loh et al. BMC Psychiatry           (2019) 19:12 Page 5 of 10
The duration of intervention with levothyroxine therapy in
these studies ranged from 2 to 12months, with a mean dur-
ation of 5.95 ± 4.09months. All but one study [17] reported
a significant improvement in TSH with levothyroxine ther-
apy (pooled d + = − 8.09, 95% CI -12.56 to − 3.63; p < 0.001).
Three studies showed significant reduction in depression
scores, from 10.3 ± 4.6 pre-treatment to 6.3 ± 3.4 post treat-
ment, p= 0.00 (HDRS) [22], from 8.3 ± 5.2 pre-treatment to
5.8 ± 4.9 post-treatment p < 0.05 (HDRS) [16], and from
16.79 ± 13.25 pre-treatment to 12.37 ± 10.01 post-treatment,
p= 0.04 (BDI) [38]. However, pooled analysis using
random-effects modelling revealed no significant improve-
ment in either BDI scores (pooled d + = − 1.05, 95% CI -2.72
to 0.61; p= 0.215) (Fig. 4) or HDRS (pooled d + = − 2.38,
95% CI -4.86 to 0.10; p = 0.060) (Fig. 5).
Discussion
Present updated meta-analysis of 21 studies reported
nearly 2.5-fold excess risk of depression in adults with
SCH, particularly in elderly population, compared with
Odds ratio meta-analysis plot [random effects]
0.2 0.5 1 2 5 10
Silva 2014 2.76 (1.31, 6.05)
De Jongh 2011 1.29 (0.60, 2.57)
Park 2009 1.04 (0.43, 2.23)
Chueire 2003 2.31 (1.11, 4.88)
combined [random] 1.72 (1.10, 2.70)
odds ratio (95% confidence interval)
Fig. 3 Risk of depression among geriatric patients with subclinical hypothyroidism
Table 2 Characteristics of studies assessing TSH level in depression
Author, year Country Setting Depression
Scale
MDD
pts, n
M:F Mean age
(SD) or age
range
SCH
pts,
n
Mean
TSH mIU/
L (SD)
Non
MDD
pts, n
M:F Mean age
(SD) or age
range
Mean
TSH mIU/
L (SD)
NOS
score
Boral 1980 India Out-patient NA 31 16:15 22–52 NA 4.58
(1.17)
31 16:15 22–52 3.07
(0.334)
8
Maes 1993 Belgium In-patient HDRS 57 20:37 54.2 (1.7) 0 0.99 (0.1) 69 33:36 40.8 (1.4) 1.67
(0.11)
8
Custro 1994 Italy In-patient BDI 9 0:9 30–69 5 1.73 (0.3) 38 0:38 49.9 1.17
(0.05)
7
Vandoolaeghe
1997
Belgium In-patient HDRS 36 20:16 50.3 (14.0) 1 1.44
(1.02)
15 10:5 47.5 (15.0) 1.73
(0.99)
8
Saxena 2000 India Out-patient NA 32 21:11 36.2 (11.8) 6 3.51
(1.78)
11 5:6 30.54 (12.6) 3.27
(0.97)
8
Almeida 2011 Australia Community GDS 189 189:0 75.9 (4.3) 17 2.2 (1.3) 3742 3742:0 75.2 (4.1) 2.3 (2.0) 8
Saltevo 2015 Finland Community BDI 236 0:236 61 (9) NA 1.97
(1.38)
1114 0:1114 59 (8) 1.92
(1.18)
8
Saltevo 2015 Finland Community BDI 163 163:0 62 (9) NA 1.94
(1.25)
1136 1136:0 60 (8) 1.87
(1.24)
8
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their euthyroid counterparts. Our findings can poten-
tially influence the clinical practice and improve the
quality of life of patients.
The association between mood disorders and changes
in the HPT axis has been recognized, although this is
frequently reported in individuals with overt hyper
−/hypothyroidism [5, 39–41]. In the central nervous sys-
tem, alterations in hormones levels such as somatostatin
and serotonin, can result in neuropsychiatric distur-
bances [42]. Existing evidence also suggests that these
mechanisms can potentially affect the HPT axis and
thus, explain the association between SCH and depres-
sion. Several studies reported a reduction in the somato-
statin level in cerebrospinal fluid, leading to increased
TSH level among individuals with depression [43, 44].
On the other hand, serotonin deficiency, which is also
commonly seen in those with depression, has been pos-
tulated to cause alterations in the HPT axis [45]. Taken
together, SCH and depression may share common bio-
logical mechanisms, which is in support of our findings.
Traditionally, depression is reported among people aged
35–45 years [46]. Of note, it has become increasingly com-
mon in the elderly as normal aging itself is associated with
biochemical changes in the HPT axis. The secretion of thy-
roid hormones is reduced with increasing age, with a lower
fT3 level but a relatively unchanged fT4 concentration.
Compared with the younger population, higher TSH level is
seen in the elderly due to reduced fT4 degradation and its
peripheral conversion to fT3, with subsequent positive feed-
back to the HPT axis [47]. Individuals with overt
Fig. 4 Changes in BDI scores with levothyroxine treatment
Fig. 5 Changes in HDRS scores with levothyroxine treatment
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hypothyroidism experience a wide variety of clinical signs
and symptoms including cold intolerance, weight gain, cog-
nitive dysfunction and mood disturbances [48, 49]. It is im-
portant to note that only up to 30% of individuals with SCH
share similar clinical features [50], with the elderly group ex-
perience even fewer and more subtle complaints, which re-
sults in a delayed diagnosis of SCH [51]. Given the world
population ageing and an increased risk of depression in the
elderly with SCH as shown in our analysis [52], there is an
urgent need for TSH and depression screening in this vul-
nerable population, in order to improve health and
well-being for all.
Although our findings showed no significant difference
in the serum TSH level between individuals with depres-
sion and healthy controls, this could possibly be a
phenomenon known as the “brain hypothyroidism” [6],
which represented a low intracerebral fT3 concentration
with normal peripheral thyroid hormones and TSH
levels [53]. Physiologically, type II deiodinase converts
fT4 to fT3 in the brain glial cells [54]. However, it has
been postulated that depression can cause inhibitory ef-
fect on type II deiodinase, which leads to the conversion
of fT4 to rT3 via type III deiodinase [55]. Furthermore,
transthyretin, a serum transport protein for fT4 in cere-
brospinal fluid, is reduced in individuals with refractory
depression [53]. Ultimately, these result in decreased in-
tracerebral fT3 and fT4 levels, along with a high rT3
concentration in cerebrospinal fluid that can also inacti-
vate fT3 activity [55, 56]. Nevertheless, further studies
which examine the variations between intracerebral and
peripheral thyroid hormones and TSH levels in different
populations are required to allow a better understanding
of this complex relationship.
Our meta-analysis did not show improvement in the
symptoms of depression with the use of levothyroxine
therapy among individuals with coexistent SCH. There are
several possible explanations. Of the six studies included,
the duration of intervention was relatively short and
heterogenous (mean: 6months, range: 2–12months),
which might contribute to the differential effects seen with
levothyroxine therapy. On the other hand, given a reduced
activity of intracerebral type II deiodinase in depression,
levothyroxine therapy might be converted to rT3 that
could exacerbate the existing intracerebral fT3 deficiency.
In a seminal series of nine individuals with refractory de-
pression, on top of antidepressant and levothyroxine ther-
apy, additional administration of liothyronine was
associated with marked improvement in the symptoms of
depression in seven of them [57]. To date, the evidence re-
lated to the effect of normalization in thyroid hormones
and TSH level in depression is inconclusive, perhaps due
to the type of thyroid hormone replacement therapy used
(single or combination), severity of SCH and depression,
timing and duration of intervention.
To the best of our knowledge, our report has explored
further in details the relationship between SCH and depres-
sion, by including the geriatric cohort and examining the
effect of levothyroxine therapy in individuals with these
co-existing illnesses. Importantly, our analysis indicated a
clear negative impact of SCH in depression. However, our
study has a few limitations. Meta-analyses are known to be
confounded by the comprehensiveness of search strategy,
reporting quality of included studies, publication bias and
exclusion of non-English articles. In this analysis, explicit
criteria were applied in our extensive literature search and
investigators were contacted for clarification whenever ne-
cessary. Besides, the study populations were considerably
older with a mean age of 52 years, which could limit the
generalizability of our results.
Conclusions
Our findings favor early and routine screening for depres-
sion among individuals with SCH especially the elderly, to
prevent morbidity and mortality. However, the use of
levothyroxine therapy among people with depression need
to be considered carefully on an individual basis, weighing
the risks and benefits of the treatment. More well-designed
population-based prospective studies or randomized con-
trolled trials are needed to gain more insights of the patho-
genesis and natural history of depression in SCH, as well as
the efficacy and safety of levothyroxine therapy to improve
mood disorders among these high-risk individuals of vary-
ing age groups.
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